^
Association details:
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
Title:

Metastatic Merkel cell carcinoma response to nivolumab

Published date:
08/18/2020
Excerpt:
...a case of a man in his 80s...Pathology demonstrated morphologic and immunohistochemical (strongly cytokeratin-20, neuron specific enolase and CD56 positive and thyroid transcription factor-1 negative) findings in both lesions consistent with MCC...subsequently treated with nivolumab 3 mg/kg intravenously every 2 weeks for six cycles in 2015. He completely recovered with a slow steroid taper, and no further treatment with nivolumab was given.
DOI:
http://dx.doi.org/10.1186/s40425-016-0186-1